SecBot SecBot
8-K ·Filed Mar 5, 2026

MRNA

Moderna, Inc.
BEARISH
Impact 8/10
Horizonmonths Processed8mo ago SEC0001682852-26-000047
8-K Item 1.01 + 5.02 (likely routine officer/director compensation agreement)
Actionable Insight ▼ Bearish

Traders should monitor the outcome of Moderna's appeal to the Federal Circuit, as a negative ruling could trigger a $1.3 billion payment. The settlement removes long-term royalty uncertainty for Moderna's vaccine pipeline but creates near-term cash flow pressure.

DirectionBearish
Confidencehigh
Horizonmonths

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$53.65
T+0 close · Mar 5, 2026 · via day close
Latest settled
−14.15%
T+60 · $46.06
Vs SPY
−25.45%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 5 $53.65entry
  2. T+1 · 9mo ago −2.18%α −0.87% · $52.48
  3. T+5 · 8mo ago −0.84%α +1.40% · $53.20
  4. T+20 · 8mo ago −8.52%α −4.73% · $49.08
  5. T+60 · 6mo ago −14.15%α −25.45% · $46.06
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Moderna entered into a settlement agreement with Arbutus Biopharma and Genevant Sciences to resolve all ongoing patent infringement litigation related to its vaccines, including Spikevax and mRESVIA. Moderna will make a $950 million noncontingent payment by July 8, 2026, and may face an additional $1.3 billion contingent payment depending on the outcome of its appeal regarding U.S. government contract protections under 28 U.S.C. 1498.

Key Financial Metrics

Deal Value
$950.0M
Deal Type
settlement

Key Facts

  • Moderna agreed to pay $950 million noncontingent lump sum to Arbutus/Genevant by July 8, 2026.
  • An additional contingent payment of up to $1.3 billion may be required if Moderna loses its appeal on 28 U.S.C. 1498 defense.
  • The settlement resolves all worldwide litigation related to Spikevax, mRESVIA, and provides certainty for Moderna's infectious disease portfolio with no future royalties.
  • If the Federal Circuit rules that 1498 bars infringement claims for some vaccine doses, the contingent payment will be prorated.
  • Arbutus/Genevant must return the contingent payment plus interest if a final decision later favors Moderna.

Financial Impact

Immediate cash outflow of $950 million and potential additional liability of up to $1.3 billion, representing approximately 5.7% of Moderna's $22.8B market cap if fully paid.

cashFlowliquiditydebtnetIncome

Risk Factors

  • Contingent $1.3 billion payment obligation if Moderna loses its 1498 appeal
  • Potential cash flow strain from large near-term payment
  • Market perception of admitting infringement liability despite appeal

Market Snapshot

Exchange
Nasdaq
Analyst Consensus
10% bullish (30 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001682852-26-000047
Document: 0001682852-26-000047-index-headers.html0001682852-26-000047
Document: 0001682852-26-000047-index.html0001682852-26-000047
Document: 0001682852-26-000047.txt0001682852-26-000047

Track record

26 reports on MRNA

Performance horizon

5 of 7 bullish or bearish reports moved the stock their way by T+1. Best: +12.10% at T+5 after the Aug 31, 2026 report. 6 of 7 went positive at some point.

Filters
  1. Nov 16, 2026today 144 Neutral 3/10 Entry $217.29 Now $215.27 −0.93% settles Nov 17
  2. Nov 13, 20263d ago 8-K Neutral 3/10 Entry $222.50 Now $215.27 −3.25% settles Nov 17
  3. Nov 6, 202610d ago 8-K Bullish 7/10 Entry $254.19 to $269.00 Now $215.27 −15.31% ▲ +5.83% +3.46% vs SPY
  4. Nov 5, 202611d ago SC 13G/A Neutral 3/10 Entry $241.46 to $254.19 Now $215.27 −10.85% ▲ +5.27% +4.96% vs SPY
  5. Oct 28, 202619d ago Institutional Cluster Neutral 3/10 Entry $214.17 to $222.76 Now $215.27 +0.52% ▲ +4.01% +4.40% vs SPY
  6. Oct 27, 202620d ago ANALYST-DOWNGRADE Bearish 4/10 Entry $207.97 to $214.17 Now $215.27 −3.51% ▼ −2.98% −2.63% vs SPY
  7. Sep 30, 20266w ago 8-K Neutral 3/10 Entry $192.57 to $188.94 Now $215.27 +11.79% ▼ −1.89% −2.06% vs SPY
  8. Sep 30, 20266w ago ANALYST-DOWNGRADE Bearish 4/10 No price data
  9. Sep 16, 20268w ago Insider Cluster Bearish 5/10 Entry $158.07 to $154.04 Now $215.27 −36.19% ▲ +2.55% +2.43% vs SPY
  10. Sep 3, 202610w ago ANALYST-DOWNGRADE Bearish 6/10 Entry $148.87 to $145.55 Now $215.27 −44.60% ▲ +2.23% +1.84% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens in 6h 26m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 5, 2026